Head-to-head evidence
Acellbia vs SAR448501
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
Acellbia
Developed by Biocad
NCT02744196 · Phase 3 · completed
This was a randomized, triple-blinded, placebo-controlled trial with 159 patients and a validated disease-response primary endpoint (ACR20). The result was clearly positive: 65.7% of Acellbia-treated patients achieved ACR20 at week 24 versus 29.4% on placebo (p<0.0001).
SAR448501
Developed by Sanofi
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2029 · NCT06647069 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acellbia's landscape · SAR448501's landscape